Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Eteplirsenexondys51.com · Low evidenceEXONDYS 51 is the first FDA-approved treatment for Duchenne muscular dystrophy in patients with a confirmed genetic mutation treatable by skipping exon 51. The therapy works by helping some patients produce a shorter form of the dystrophin protein, a marker considered likely to predict clinical benefit.
Parse Score